Smithkline Beecham Corporation

Ed Williams McLean

Wieslaw Mieczyslaw Kazmierski

Stephen Andrew Thomson

Jerzy Ryszard Szewczyk

Maosheng Duan

Dulce Garrido Bubacz

Pek Yoke Chong

Eric Eugene Boros

Jennifer Poole Peckham

Cecilia Suarez Koble

Jennings Franklin Worley, Iii

James Benjamin Thompson

Felix Deanda, Jr

Neil Bifulco, Jr

Chrisopher Joseph Aquino

Brian Andrew Chauder

Angilique C Perkins

Dana Vanderwall

Andrew James Peat

Robert Anderson Noe

Iain David Dukes

The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

CCR5 antagonists as therapeutic agents

The invention relates to methods of treatment of non insulin dependent diabetes mellitus, antagonists of the delayed rectifier potassium channel Kv2.1, methods of using and preparing the antagonists and assays for identifying such antagonists.

Kv2.1 antagonists

Growing community of inventors

Durham, NC, United States of America

Ed Williams McLean